Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive–compulsive disorder by integrated bioinformatics analysis

[1]  S. Brand,et al.  Identification of key long non-coding RNA-associated competing endogenous RNA axes in Brodmann Area 10 brain region of schizophrenia patients , 2022, Frontiers in Psychiatry.

[2]  S. Pençe,et al.  Can miRNA Expression Levels Predict Treatment Resistance to Serotonin Reuptake Inhibitors in Patients with Obsessive-Compulsive Disorder? , 2022, Psychiatry and Clinical Psychopharmacology.

[3]  A. Merikangas,et al.  What genes are differentially expressed in individuals with schizophrenia? A systematic review , 2022, Molecular Psychiatry.

[4]  F. Alizadeh,et al.  Serotonin transporter functional polymorphisms potentially increase risk of schizophrenia separately and as a haplotype , 2022, Scientific Reports.

[5]  Yanqing Liu,et al.  Altered expression levels of miR-144-3p and ATP1B2 are associated with schizophrenia , 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[6]  Tudor I. Oprea,et al.  Getting Started with the IDG KMC Datasets and Tools , 2022, Current protocols.

[7]  Kimberly Burns,et al.  Pharmacological and philosophical considerations for the around-the-clock use of scheduled melatonin to promote sedation and reduce aggression in individuals with serious mental illness: a case report , 2021, International clinical psychopharmacology.

[8]  N. Bokhan,et al.  Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms , 2021, Life.

[9]  D. Castle,et al.  Therapeutic use of melatonin in schizophrenia: A systematic review , 2021, World journal of psychiatry.

[10]  P. Asgari,et al.  Treatment Approaches Based on Neuroscientific Data in Patients With Obsessive-Compulsive Disorder , 2021, International Clinical Neuroscience Journal.

[11]  T. Werge,et al.  Polygenic Heterogeneity Across Obsessive-Compulsive Disorder Subgroups Defined by a Comorbid Diagnosis , 2021, Frontiers in Genetics.

[12]  Henning Hermjakob,et al.  IntAct App: a Cytoscape application for molecular interaction network visualization and analysis , 2021, Bioinform..

[13]  Mo Li,et al.  Genome-wide association study of antipsychotic-induced sinus bradycardia in Chinese schizophrenia patients , 2021, PloS one.

[14]  Kathleen M. Jagodnik,et al.  Gene Set Knowledge Discovery with Enrichr , 2021, Current protocols.

[15]  R. Maiti,et al.  Effect of Haloperidol and Risperidone on Serum Melatonin and GAP-43 in Patients with Schizophrenia: A Prospective Cohort Study , 2021, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[16]  A. Shahbazi,et al.  A Computational-Based Drug Repurposing Method Targeting SARS-CoV-2 and its Neurological Manifestations Genes and Signaling Pathways , 2021, Bioinformatics and biology insights.

[17]  J. Wan,et al.  Construction of lncRNA-related ceRNA regulatory network in diabetic subdermal endothelial cells , 2021, Bioengineered.

[18]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[19]  S. Deshpande,et al.  Schizophrenia with and without obsessive-compulsive symptoms: a comparative analysis of performance on trail making test and disability on WHODAS , 2020, General Psychiatry.

[20]  Mohammad Safiqul Islam,et al.  Association of DRD2 gene polymorphisms with schizophrenia in the young Bangladeshi population: A pilot study , 2020, Heliyon.

[21]  G. Hall,et al.  The association of HTR2A polymorphisms with obsessive-compulsive disorder and its subtypes: A meta-analysis. , 2020, Journal of affective disorders.

[22]  A. Bozorgmehr,et al.  An integrative gene network-based approach to uncover the cellular and molecular infrastructures of schizophrenia. , 2020, Life sciences.

[23]  Ming Xu,et al.  MiR-3121-3p promotes tumor invasion and metastasis by suppressing Rap1GAP in papillary thyroid cancer in vitro , 2020, Annals of translational medicine.

[24]  J. Kantrowitz,et al.  Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches , 2020, CNS Drugs.

[25]  K. Hong,et al.  Clozapine generates obsessive compulsive disorder-like behavior in mice , 2020, Molecular Brain.

[26]  A. V. van Balkom,et al.  Classification of comorbidity in obsessive–compulsive disorder: A latent class analysis , 2020, Brain and behavior.

[27]  A. Bozorgmehr,et al.  How obsessive–compulsive and bipolar disorders meet each other? An integrative gene-based enrichment approach , 2020, Annals of General Psychiatry.

[28]  A. Merikangas,et al.  Using the tools of genetic epidemiology to understand sex differences in neuropsychiatric disorders , 2020, Genes, brain, and behavior.

[29]  N. Pivac,et al.  HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia , 2020, International journal of molecular sciences.

[30]  W. Honer,et al.  Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases , 2019, Psychotherapy and Psychosomatics.

[31]  Zieske Maritska,et al.  DRD2 Gene Polymorphisms in Schizophrenia Patients , 2020, Proceedings of the 1st Jenderal Soedirman International Medical Conference in conjunction with the 5th Annual Scientific Meeting (Temilnas) Consortium of Biomedical Science Indonesia.

[32]  Jun Yao,et al.  A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia , 2019, Journal of Molecular Neuroscience.

[33]  Pradeep Kumar,et al.  Catechol-O-methyltransferase gene Val158Met polymorphism and obsessive compulsive disorder susceptibility: a meta-analysis , 2019, Metabolic Brain Disease.

[34]  P. Srivastava,et al.  Analysis and subsequent molecular docking of selected phytochemicals with SLC6A3 and SLC6A4 as potential therapeutic agents for Obsessive-Compulsive Disorder (OCD) , 2019 .

[35]  B. Pignon,et al.  Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature , 2019, Current Psychiatry Reports.

[36]  P. Yan,et al.  Is Brain-Derived Neurotrophic Factor (BDNF) Val66Met Polymorphism Associated with Obsessive-Compulsive Disorder? A Meta-Analysis. , 2019, Psychiatria Danubina.

[37]  R. Edden,et al.  Investigation of anterior cingulate cortex gamma-aminobutyric acid and glutamate-glutamine levels in obsessive-compulsive disorder using magnetic resonance spectroscopy , 2019, BMC Psychiatry.

[38]  J. Coyle,et al.  Glutamate hypothesis in schizophrenia , 2019, Psychiatry and clinical neurosciences.

[39]  K. Turkmani,et al.  Haloperidol discontinuation for people with schizophrenia. , 2019, The Cochrane database of systematic reviews.

[40]  T. Jaisoorya,et al.  Antipsychotic augmentation in the treatment of obsessive-compulsive disorder , 2019, Indian journal of psychiatry.

[41]  Jun Yao,et al.  Association between the SLC6A4 gene and schizophrenia: an updated meta-analysis , 2018, Neuropsychiatric disease and treatment.

[42]  B. Camarena,et al.  Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia , 2018, Neuropsychiatric disease and treatment.

[43]  Jihan Wang,et al.  Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia , 2018, Psychiatry Research.

[44]  Neda Jahanshad,et al.  Significant concordance of genetic variation that increases both the risk for obsessive-compulsive disorder and the volumes of the nucleus accumbens and putamen. , 2018, The British journal of psychiatry : the journal of mental science.

[45]  S. Stahl.  Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate , 2018, CNS Spectrums.

[46]  A. Mohammadi,et al.  Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia , 2018, Psychiatry Research.

[47]  R. Emsley,et al.  The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder , 2018, Molecular and Cellular Neuroscience.

[48]  Leonardo Franklin Fontenelle,et al.  Association analysis of SLC6A4 and HTR2A genes with obsessive-compulsive disorder: Influence of the STin2 polymorphism. , 2018, Comprehensive psychiatry.

[49]  M. Pompili,et al.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine , 2018, Therapeutic advances in drug safety.

[50]  J. Parent,et al.  PlexinA2 Forward Signaling through Rap1 GTPases Regulates Dentate Gyrus Development and Schizophrenia-like Behaviors , 2018, Cell reports.

[51]  A. Ahmadiani,et al.  Association of the functional serotonin transporter haplotype with familial form of obsessive compulsive disorder in Iranian patients , 2018, International journal of psychiatry in clinical practice.

[52]  C. Burton,et al.  A review of the role of serotonin system genes in obsessive-compulsive disorder , 2017, Neuroscience & Biobehavioral Reviews.

[53]  Lin He,et al.  MiRNAs of peripheral blood as the biomarker of schizophrenia , 2017, Hereditas.

[54]  Sang-Yoon Lee,et al.  Altered interregional correlations between serotonin transporter availability and cerebral glucose metabolism in schizophrenia: A high-resolution PET study using [11C]DASB and [18F]FDG , 2017, Schizophrenia Research.

[55]  Tih-Shih Lee,et al.  GAD1 Gene Expression in Blood of Patients with First-Episode Psychosis , 2017, PloS one.

[56]  C. Pariante,et al.  The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders , 2016, Translational psychiatry.

[57]  F. Lee,et al.  The Role of BDNF in the Development of Fear Learning , 2016, Depression and anxiety.

[58]  Scott J. Myers,et al.  Human GRIN2B variants in neurodevelopmental disorders , 2016, Journal of pharmacological sciences.

[59]  G. He,et al.  A study of single nucleotide polymorphisms of GRIN2B in schizophrenia from Chinese Han population , 2016, Neuroscience Letters.

[60]  Andrew D. Rouillard,et al.  The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins , 2016, Database J. Biol. Databases Curation.

[61]  X. Estivill,et al.  Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia , 2016, Translational Psychiatry.

[62]  Seshadri Sekhar Chatterjee,et al.  Emerging Hyperprolactinemic Galactorrhea in Obsessive Compulsive Disorder with a Stable Dose of Fluoxetine , 2015, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[63]  S. Selek,et al.  Microribonucleic acid dysregulations in children and adolescents with obsessive–compulsive disorder , 2015, Neuropsychiatric disease and treatment.

[64]  Ming-dao Zhang,et al.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk , 2015, Neuropsychiatric disease and treatment.

[65]  R. Quartesan,et al.  History and Conceptual Problems of the Relationship Between Obsessions and Hallucinations , 2015, Harvard review of psychiatry.

[66]  Yuhan Wang,et al.  microRNAs as novel biomarkers of schizophrenia (Review) , 2014, Experimental and therapeutic medicine.

[67]  D. Atkinson,et al.  Schizophrenia: overview and treatment options. , 2014, P & T : a peer-reviewed journal for formulary management.

[68]  M. Zink.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment , 2014, Advances in medicine.

[69]  K. Ohi,et al.  Functional polymorphism (C‐824T) of the tyrosine hydroxylase gene affects IQ in schizophrenia , 2014, Psychiatry and clinical neurosciences.

[70]  F. Smit,et al.  The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates , 2014, Schizophrenia Research.

[71]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[72]  M. Zink,et al.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors , 2013, Front. Pharmacol..

[73]  G. Michlewski,et al.  miRNAs in development and pathogenesis of the nervous system. , 2013, Biochemical Society transactions.

[74]  S. Taylor,et al.  Molecular genetics of obsessive–compulsive disorder: a comprehensive meta-analysis of genetic association studies , 2013, Molecular Psychiatry.

[75]  R. Nieto,et al.  BDNF and Schizophrenia: From Neurodevelopment to Neuronal Plasticity, Learning, and Memory , 2013, Front. Psychiatry.

[76]  D. Cardinali,et al.  Sleep and circadian rhythm dysregulation in schizophrenia , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[77]  S. E. Stewart,et al.  Meta‐analysis of association between obsessive‐compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1 , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[78]  Abraham Weizman,et al.  Escitalopram in the treatment of patients with schizophrenia and obsessive–compulsive disorder: an open-label, prospective study , 2013, International clinical psychopharmacology.

[79]  Z. J. Huang,et al.  Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia , 2013, Neurobiology of Disease.

[80]  M. Gratacós,et al.  Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. , 2012, Journal of psychiatry & neuroscience : JPN.

[81]  R. Quartesan,et al.  Schizophrenia and obsessive-compulsive disorder: from comorbidity to schizo-obsessive disorder. , 2012, Rivista di psichiatria.

[82]  K. Audenaert,et al.  Serotonin 2A receptor, serotonin transporter and dopamine transporter alterations in dogs with compulsive behaviour as a promising model for human obsessive-compulsive disorder , 2012, Psychiatry Research: Neuroimaging.

[83]  Michael A. Langston,et al.  GeneWeaver: a web-based system for integrative functional genomics , 2011, Nucleic Acids Res..

[84]  A. Achim,et al.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. , 2011, Schizophrenia bulletin.

[85]  Károly Mirnics,et al.  ynaptic changes in the brain of subjects with schizophrenia , 2011 .

[86]  Yong-Ku Kim,et al.  Effect of Serotonin-Related Gene Polymorphisms on Pathogenesis and Treatment Response in Korean Schizophrenic Patients , 2011, Behavior genetics.

[87]  Chia-Hsiang Chen,et al.  Genetic and Functional Analysis of the DLG4 Gene Encoding the Post-Synaptic Density Protein 95 in Schizophrenia , 2010, PloS one.

[88]  Chan-Hyung Kim,et al.  Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder , 2010, Expert review of neurotherapeutics.

[89]  J. A. Boer,et al.  The role of the brain‐derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive‐compulsive disorder (OCD) , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[90]  A. Dasgupta,et al.  Study of oxidative stress in obsessive compulsive disorder in response to treatment with Fluoxetine , 2009, Indian Journal of Clinical Biochemistry.

[91]  Guoping Feng,et al.  Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder , 2008, Current chemical genomics.

[92]  Leonardo Franklin Fontenelle,et al.  The Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. , 2008, Revista brasileira de psiquiatria.

[93]  Alessandra Gorini,et al.  In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder , 2008, NeuroImage.

[94]  K. Martinowich,et al.  Cell biology of BDNF and its relevance to schizophrenia. , 2008, Novartis Foundation symposium.

[95]  K. Hornik,et al.  Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder , 2008, Neuropsychopharmacology.

[96]  D. Stein,et al.  Investigating the role of the brain-derived neurotrophic factor (BDNF) val66met variant in obsessive-compulsive disorder (OCD) , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[97]  Keri Martinowich,et al.  Interaction between BDNF and Serotonin: Role in Mood Disorders , 2008, Neuropsychopharmacology.

[98]  Peter F. Buckley,et al.  Neurotrophins and schizophrenia , 2007, Schizophrenia Research.

[99]  H. Westenberg,et al.  Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive–compulsive disorder in males , 2006, European Neuropsychopharmacology.

[100]  S. Rasmussen,et al.  The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. , 2006, The Journal of clinical psychiatry.

[101]  M. Richter,et al.  Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? , 2005, Journal of psychiatry & neuroscience : JPN.

[102]  Abraham Weizman,et al.  Obsessive-Compulsive Disorder in Schizophrenia , 2004 .

[103]  M. Karayiorgou,et al.  Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. , 2003, American journal of human genetics.

[104]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[105]  J. Benson,et al.  BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABAA receptor surface expression , 2001, The European journal of neuroscience.

[106]  S. Rauch,et al.  Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. , 2000, The Psychiatric clinics of North America.

[107]  P. Sokoloff,et al.  Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia , 2000, Molecular Psychiatry.

[108]  G. Rosoklija,et al.  Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. , 2000, Archives of general psychiatry.

[109]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[110]  T. Pigott,et al.  A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. , 1999, The Journal of clinical psychiatry.

[111]  M. Maj,et al.  Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. , 1997, Neuropsychobiology.

[112]  M. Maj,et al.  Circadian rhythms of melatonin, cortisol and prolactin in patients with obsessive‐compulsive disorder , 1994, Acta psychiatrica Scandinavica.

[113]  I. Nir,et al.  Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients , 1991, Acta psychiatrica Scandinavica.

[114]  M. Marie-cardine,et al.  Nocturnal plasma melatonin levels in schizophrenic patients , 1989, Biological Psychiatry.